Seek the latest state of technical research in biology

Summary. Hello dear, happy to answer your <>

In the field of biotechnology, the biggest development prospect is the breakthrough of genetically modified technology and bioinformation technology. The development of genetically modified technology will help people directly modify the genes of plants and animals to make them more adaptable to the environment, it can change the quality of products, increase yields, etc., and bring lower food and drug costs. In addition, genetically modified technology also has great prospects in various fields such as agriculture, medicine, and light industry.

Prospects and trends of biotechnology.

Hello dear, I'm glad to answer your <>

In the field of biotechnology, the biggest development prospect is the breakthrough of genetically modified technology and Xiaoling rolling bioinformation technology. The development of genetically modified technology will help people directly modify the genes of plants and animals to make them more adaptable to the environment, which can change the quality of products, increase yields, etc., and bring lower food and drug costs. In addition, genetically modified technology also has great prospects in various fields such as agriculture, medicine, and light industry.

<>Bioinformatics, also known as gene molecular informatics, is a related science that applies complex molecular biology, computer technology, systems biology, statistics, and other related sciences to study the genes of an organism by analyzing and comparing the structure and function of gene combinations. At present, bioinformation technology is spreading in a big way, mainly in the fields of pathogenic fungi, plants, animal viruses and cancer. The development of biotechnology provides great potential for agriculture, medicine, environment and other industries.

1. The biotechnology major is promising. The program requires graduates to have a high level of professional knowledge and skills. Graduates are mainly engaged in scientific research, teaching and senior management in scientific research institutions, colleges and universities, and state agencies.

2. Biotechnology has always been a key industrial field supported by the company, and cutting-edge research, including cloning, is carried out with the strong support of the company, so the employment status of related biology majors has always tended to be a good development.

3. Whether it is in research institutions or biological companies, investment has increased every year. And the growth rate of jobs has also remained at around 4-5%. With the rapid development of science and technology, the division of science and technology is becoming more and more detailed, and the interdisciplinary nature is becoming stronger and stronger, and many emerging disciplines related to biology are in the ascendant.

In addition, biology-related applied disciplines include public health, food, nutrition, etc., and the talent gap is also larger than that of basic research.

The employment direction of biotechnology majors is various biological product companies, most of which are biopharmaceutical, alcoholic, beverage, food, health care products, etc. The fields of practice include postgraduate entrance examinations, civil servants, laboratory and laboratory physicians, scientific research personnel, sales representatives, high school teachers, bioengineering, biopharmaceuticals, and personnel of public institutions. At present, the demand for talents in biotechnology majors is mainly reflected in the cutting-edge, so the employment prospects of Yesha Ran undergraduate graduates are very difficult, but it is still very good for high-level talents.

The main employment direction of graduates is various biological product companies, most of which are biopharmaceutical, alcoholic, beverage, food, health care products, etc.

First, the development.

The study of human genomics after BAI has mastered the birth and old age diseases of human beings.

The natural law of DAO death.

About Genomics.

In a nutshell, all genes are identified in the base pair sequence of the figure; secondly, to identify the biochemical structure and properties of each gene; Finally, it is necessary to understand the relationship between all genes and humans.

Postgenomics can lead to several branches of structural domains, including structural genomics, genomics, proteomics, and so on.

2. Strengthen the research and development of various new biotechnology drugs.

3. Gradually carry out in-depth research on genetic diagnosis and genetic research.

At present, the more mature ones are anemia and leukemia. Genetic diagnosis of uremia, diabetes, Japanese encephalitis virus, hepatitis C virus, HIV, Mycobacterium tuberculosis.

Fourth, the production of drugs through genetically modified animals, the establishment of high-quality animal husbandry lines through the cloning of animals, and the rescue of endangered animals.

5. Carry out research on marine biology.

6. Vigorously carry out research in biotechnology-related engineering and technology disciplines, such as biochemical engineering, biomedical engineering, bioinformatics, etc.

7. Strengthen cooperative research with environmental protection disciplines, such as using an alkaloidogenic bacillus that can use the properties of terephthalic acid to treat wastewater from dye factories. Carry out biological remediation.

2.The history of biotechnology, traditional biotechnology, modern biotechnology.

The field of modern biotechnology is so big and so wide.

Basically covering medicine, agronomy, industry, I don't know which aspect or which field you want to know about the latest progress?

In 2019, China's biopharmaceutical enterprises above designated size achieved more than 23% of their main business income0 billion yuan

According to the "2012-2018 Completion of Main Economic Indicators of the Pharmaceutical Industry" issued by the Consumer Goods Department of the Ministry of Industry and Information Technology, in 2018, China's biomedical enterprises above designated size achieved main business income of 100 million yuan, a year-on-year decline. At present, the Ministry of Industry and Information Technology has not released the industry data for 2019, and due to the decline in vaccine issuance in 2019, it is estimated that the main business income of China's biopharmaceutical enterprises above designated size in 2019 will be about 232.1 billion yuan.

From 2012 to 2018, the total profit of China's biomedical industry showed a fluctuating trend, and in 2018, the total profit of enterprises above designated size in China's biomedical industry reached 100 million yuan, a year-on-year decline. At present, the Ministry of Industry and Information Technology has not released the industry data for 2019, and due to the decline in vaccine issuance in 2019, it is estimated that the total profit of China's biomedical enterprises above designated size in 2019 will be about 100 million yuan.

In 2019, the total number of vaccine batches issued nationwide was 100 million

With the rapid development of China's vaccine market, especially after several major epidemics, the public's awareness of vaccines has been improved to varying degrees. From the perspective of the total number of batches issued, the number of vaccine batches issued from 2010 to 2015 continued to decline, and by 2015, it had dropped to 100 million people; It rebounded in 2016. In 2017, there were 50 varieties of vaccines applied for issuance, with a total of 4,404 batches, of which 4,388 batches (about 100 million copies) met the regulations, and 16 batches (about 10,000 copies) did not meet the requirements.

In 2018, the cumulative batch issuance of vaccines in China was 100 million, a year-on-year decrease. In 2019, the total number of vaccine batches issued nationwide was 100 million, a year-on-year decrease.

In 2025, the market size of China's biomedical industry will exceed 500 billion yuan

Blood products are the most important subdivided products in China's biomedical industry, which directly affects the market prospects of the biomedical industry. In 2020, driven by the epidemic, the field of blood products returned to the boom. The epidemic has promoted the performance of blood product companies in the first quarter of 2020 or accelerated growth, and there is a possibility of price increases for some products.

Forward-looking prediction, under the influence of the epidemic and the country's emphasis on the biomedical industry, the market size of China's biomedical industry will return to the growth rate of 10%-15% before 2017 from 2020 to 2025, and it is expected that the market size of China's biomedical industry will exceed 500 billion yuan by 2025.

——The above data ** in the Prospective Industry Research InstituteAnalysis report on market prospect and investment strategic planning of China's biopharmaceutical industry